You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

List of Excipients in API sunitinib malate


✉ Email this page to a colleague

« Back to Dashboard


Excipients in NDA-approved (novel) drugs containing sunitinib malate

Glossary
Company Tradename Ingredient NDC Excipient Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc SUTENT sunitinib malate 0069-0550 CROSCARMELLOSE SODIUM
Pfizer Laboratories Div Pfizer Inc SUTENT sunitinib malate 0069-0550 FERRIC OXIDE RED
Pfizer Laboratories Div Pfizer Inc SUTENT sunitinib malate 0069-0550 GELATIN
Pfizer Laboratories Div Pfizer Inc SUTENT sunitinib malate 0069-0550 MAGNESIUM STEARATE
Pfizer Laboratories Div Pfizer Inc SUTENT sunitinib malate 0069-0550 MANNITOL
Pfizer Laboratories Div Pfizer Inc SUTENT sunitinib malate 0069-0550 POTASSIUM HYDROXIDE
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Subscribe to access the full database, or Sign Up

Excipients in ANDA-approved (generic) drugs containing sunitinib malate

Company Ingredient NDC Excipient
Teva Pharmaceuticals USA Inc sunitinib malate 0093-8199 CROSCARMELLOSE SODIUM
Teva Pharmaceuticals USA Inc sunitinib malate 0093-8199 D&C RED NO. 28
Teva Pharmaceuticals USA Inc sunitinib malate 0093-8199 D&C YELLOW NO. 10 ALUMINUM LAKE
Teva Pharmaceuticals USA Inc sunitinib malate 0093-8199 FD&C BLUE NO. 1
Teva Pharmaceuticals USA Inc sunitinib malate 0093-8199 FD&C BLUE NO. 1 ALUMINUM LAKE
Teva Pharmaceuticals USA Inc sunitinib malate 0093-8199 FD&C BLUE NO. 2--ALUMINUM LAKE
>Company >Ingredient >NDC >Excipient

Subscribe to access the full database, or Sign Up

Detailed excipient profiles for sunitinib malate

Excipient focus: AMMONIA

Excipient focus: BUTYL ALCOHOL

Excipient focus: CROSCARMELLOSE SODIUM

Excipient focus: D&C RED NO. 28

Excipient focus: D&C YELLOW NO. 10 ALUMINUM LAKE

sunitinib malate drug variants not containing D&C YELLOW NO. 10 ALUMINUM LAKE

Company Ingredient NDC
Pfizer Laboratories Div Pfizer Inc sunitinib malate 0069-0550
Mylan Pharmaceuticals Inc sunitinib malate 0378-6678
NorthStar RxLLC sunitinib malate 16714-676
DrReddys Laboratories Inc sunitinib malate 43598-045
Aurobindo Pharma Limited sunitinib malate 59651-464
Sun Pharmaceutical Industries Inc sunitinib malate 63304-091
>Company >Ingredient >NDC

Subscribe to access the full database, or Sign Up

Excipient focus: FD&C BLUE NO. 1

Excipient focus: FD&C BLUE NO. 1 ALUMINUM LAKE

Excipient focus: FD&C BLUE NO. 2--ALUMINUM LAKE

sunitinib malate drug variants not containing FD&C BLUE NO. 2--ALUMINUM LAKE

Company Ingredient NDC
Pfizer Laboratories Div Pfizer Inc sunitinib malate 0069-0550
Mylan Pharmaceuticals Inc sunitinib malate 0378-6678
NorthStar RxLLC sunitinib malate 16714-676
DrReddys Laboratories Inc sunitinib malate 43598-045
Aurobindo Pharma Limited sunitinib malate 59651-464
Sun Pharmaceutical Industries Inc sunitinib malate 63304-091
>Company >Ingredient >NDC

Subscribe to access the full database, or Sign Up

Excipient focus: FD&C RED NO. 40

Excipient focus: FERRIC OXIDE RED

Excipient focus: FERRIC OXIDE YELLOW

Excipient focus: FERROSOFERRIC OXIDE

Excipient focus: GELATIN

Excipient focus: ISOPROPYL ALCOHOL

Excipient focus: MAGNESIUM STEARATE

Excipient focus: MANNITOL

Excipient focus: POTASSIUM HYDROXIDE

Excipient focus: POVIDONE

Excipient focus: POVIDONE K25

Excipient focus: POVIDONE K30

Excipient focus: PROPYLENE GLYCOL

Excipient focus: SHELLAC

Excipient focus: SILICON DIOXIDE

Excipient focus: SODIUM HYDROXIDE

Excipient focus: SODIUM LAURYL SULFATE

Excipient focus: TITANIUM DIOXIDE

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
 NCE-1 Patent Challenge Dates 2024 - 2025
 Trigger-based marketing for the life sciences
 Get DrugPatentWatch Business Intelligence Reports at Amazon.com
 DrugChatter - AI-based answers to questions about drugs
 RxJam - Digital Marketing for Life Sciences
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group